News – All 2 results:
Bartlit Beck Wins Inter Partes Review (IPR) Trial for Gilead Sciences, Inc.
[PDF] ... of combinations identified as of special interest.” Id., see also id. at 7 (the same). Patent Owner argues that ... that “[o]ther ‘guides’ allegedly lead[] to chlorpropamide.” Id. According to the appellants, the specification disclosed eleven ...
Mark Levine Writes Article on Managing Litigation Costs
July 2009 ... express purpose of obtaining appellate review of the claim construction. Id . at 1334. However, the court explained, such stipulations are only ... to ascertain the basis for the judgment challenged on appeal." Id . at 1334-35. The court went on to find ...
Additional Documents 1 – 5 of 40:
... ); JTX265 at 1523 (correcting misstatement from first declaration); id. at 2172 (correcting misstatement from second declaration)), and ... cycle control success" with the ' 577 patent regimen. (Id. ) The assumptions Watson identifies as underlying Bayer' s ...
... claim “may be accepted for collection” by the other sovereign. Id., ¶ 3 (emphasis added). “Paragraph 3 ... clarifies that the Contracting ... ’ to the question addressed by the common law.” Id.; See also Id. at 540-41, 113 S.Ct. 1631 (Stevens, J ...
... petitioner’s counsel should have investigated further. See id. (“In assessing the reasonableness of an attorney’s ... in assessing whether [the petitioner] satisfied § 2254(d).” Id. Distinguishing Richter, the Supreme Court explained that federal ...
... racial minority in society . . . .” Id. at 2341. 44. Id. at 2340. 45. Id. 46. Id. 47. Id. (quoting Becton Brief, supra note ... of racial discrimination.” Id. at 2349 (Scalia, J., dissenting). 55. Id. at 2349. 56. Id. 57. Id. 58. Id. at 2339 (majority ...
... pharmacokinetic profile after intramuscular injection of ... testosterone enanthate." (Id. at 1:51-62) A need existed for " ... the available therapies (including an implantable pellet, Testopel). (Id. at 540-541) Dr. Schlegel explained that Testopel ...